Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles

The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope (Env) trimer protein nanoparticles are superior immunogens compared to trimers alone for priming of broadly neutralizing antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Zekun, Wiehe, Kevin, Saunders, Kevin O., Henderson, Rory, Cain, Derek W., Parks, Robert, Martik, Diana, Mansouri, Katayoun, Edwards, Robert J., Newman, Amanda, Lu, Xiaozhi, Xia, Shi-Mao, Bonsignori, Mattia, Montefiori, David, Han, Qifeng, Venkatayogi, Sravani, Evangelous, Tyler, Wang, Yunfei, Rountree, Wes, Tam, Ying, Barbosa, Christopher, Alam, S. Munir, Williams, Wilton B., Pardi, Norbert, Weissman, Drew, Haynes, Barton F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366792/
https://www.ncbi.nlm.nih.gov/pubmed/34401876
http://dx.doi.org/10.1101/2021.08.09.455714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366792/
https://www.ncbi.nlm.nih.gov/pubmed/34401876
http://dx.doi.org/10.1101/2021.08.09.455714

Ejemplares similares